These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 18566242

  • 41. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
    Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL, Cheng AL, Pu YS, Cheng JC.
    Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 44. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.
    Mol Cancer Ther; 2009 Dec 01; 8(12):3296-306. PubMed ID: 19952121
    [Abstract] [Full Text] [Related]

  • 45. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC, Tsai JJ, Weng YS, Hsu FT.
    Biomed Pharmacother; 2020 Aug 01; 128():110319. PubMed ID: 32502841
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
    Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R.
    Cancer; 2005 Aug 15; 104(4):879-90. PubMed ID: 16007726
    [Abstract] [Full Text] [Related]

  • 48. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.
    Mol Cancer Ther; 2006 Nov 15; 5(11):2676-84. PubMed ID: 17121914
    [Abstract] [Full Text] [Related]

  • 49. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
    Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, Pirker C, Gruenberger T, Filipits M.
    Mol Cancer Ther; 2009 Jun 15; 8(6):1547-56. PubMed ID: 19509244
    [Abstract] [Full Text] [Related]

  • 50. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.
    Oncol Res; 2013 Jun 15; 21(3):137-44. PubMed ID: 24512728
    [Abstract] [Full Text] [Related]

  • 51. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP.
    Cancer Biol Ther; 2007 Apr 15; 6(4):548-54. PubMed ID: 17457047
    [Abstract] [Full Text] [Related]

  • 52. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways.
    Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK.
    Int J Cancer; 2012 Nov 01; 131(9):2175-86. PubMed ID: 22322442
    [Abstract] [Full Text] [Related]

  • 53. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.
    Singh-Gupta V, Banerjee S, Yunker CK, Rakowski JT, Joiner MC, Konski AA, Sarkar FH, Hillman GG.
    Cancer Lett; 2012 May 01; 318(1):86-92. PubMed ID: 22155105
    [Abstract] [Full Text] [Related]

  • 54. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.
    Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R.
    Cancer; 2004 Nov 15; 101(10):2351-62. PubMed ID: 15476283
    [Abstract] [Full Text] [Related]

  • 55. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
    Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP.
    J Thorac Oncol; 2009 Feb 15; 4(2):161-6. PubMed ID: 19179890
    [Abstract] [Full Text] [Related]

  • 56. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 15; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 57. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.
    Mol Cancer Ther; 2015 Feb 15; 14(2):533-41. PubMed ID: 25522765
    [Abstract] [Full Text] [Related]

  • 58. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
    Kandala PK, Srivastava SK.
    BMC Med; 2012 Jan 26; 10():9. PubMed ID: 22280969
    [Abstract] [Full Text] [Related]

  • 59. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
    Jiang J, Yuan Z, Sun Y, Bu Y, Li W, Fei Z.
    Biomed Pharmacother; 2017 Dec 26; 96():619-625. PubMed ID: 29035827
    [Abstract] [Full Text] [Related]

  • 60. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z, Liao J, Yang Z, Choi EY, Lapidus RG, Liu X, Cullen KJ, Dan H.
    Br J Cancer; 2019 Feb 26; 120(3):306-316. PubMed ID: 30585254
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.